CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, and PicnicHealth, a patient-centered health technology company, today announced...
Cure Rare Disease, a clinical-stage nonprofit biotechnology company, has been awarded an advocacy collaboration grant from the Muscular Dystrophy Association (MDA) to support research on novel...
Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in...
Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced multiple major milestones for ATA-100 and ATA-200,...
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today presented...
